One-year extension study of ACCORD COPD I: Safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD

Anthony D'Urzo, Edward Kerwin, Stephen Rennard, Thomas He, Esther Garcia Gil, Cynthia Caracta

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

This was a 52-week, double-blind, extension study in which COPD patients previously treated with twice-daily (BID) aclidinium bromide 200 μg or 400 μg during a 12-week lead-in study (ACCORD COPD I) continued the same treatment, while patients previously receiving placebo were rerandomized (1:1) to aclidinium 200 μg or 400 μg BID. The primary objective of this study was to evaluate the long-term safety and tolerability of aclidinium treatment. Efficacy outcomes included bronchodilation, health status, and rescue medication use. A total of 467 patients completed the lead-in study and 291 patients consented to participate in the extension. At study end, the percentages of patients who reported a treatment-emergent adverse event (TEAE) were similar for both treatments (200 μg, 77.4%; 400 μg, 73.7%). Incidence of anticholinergic TEAEs was low and similar for both treatments, with dry mouth reported in only 1 patient (400 μg). Cardiac TEAEs were reported by a similarly low percentage of patients (<5% for any event in any group) with no apparent dose dependence. Improvements from baseline in lung function were greatest for patients who received continuous aclidinium treatment and those who were rerandomized from placebo to aclidinium 400 μg; these improvements were generally sustained throughout the study. Health status and overall rescue medication use was improved from baseline for both treatments. The safety profile of twice-daily aclidinium and sustained improvements in lung function and health status throughout the 52-week extension study support its use as a long-term maintenance treatment for patients with COPD. (Clinical trial registration number NCT00970268).

Original languageEnglish (US)
Pages (from-to)500-510
Number of pages11
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2013

Fingerprint

Chronic Obstructive Pulmonary Disease
Safety
Health Status
Therapeutics
Placebos
aclidinium bromide
Lung
Cholinergic Antagonists
Double-Blind Method
Mouth
Clinical Trials
Incidence

Keywords

  • Bronchodilation
  • Health status
  • Symptoms
  • Tolerability

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

One-year extension study of ACCORD COPD I : Safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. / D'Urzo, Anthony; Kerwin, Edward; Rennard, Stephen; He, Thomas; Gil, Esther Garcia; Caracta, Cynthia.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 10, No. 4, 01.08.2013, p. 500-510.

Research output: Contribution to journalArticle

D'Urzo, Anthony ; Kerwin, Edward ; Rennard, Stephen ; He, Thomas ; Gil, Esther Garcia ; Caracta, Cynthia. / One-year extension study of ACCORD COPD I : Safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2013 ; Vol. 10, No. 4. pp. 500-510.
@article{e8ba93c6129c4eaeb5fc051d085eafce,
title = "One-year extension study of ACCORD COPD I: Safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD",
abstract = "This was a 52-week, double-blind, extension study in which COPD patients previously treated with twice-daily (BID) aclidinium bromide 200 μg or 400 μg during a 12-week lead-in study (ACCORD COPD I) continued the same treatment, while patients previously receiving placebo were rerandomized (1:1) to aclidinium 200 μg or 400 μg BID. The primary objective of this study was to evaluate the long-term safety and tolerability of aclidinium treatment. Efficacy outcomes included bronchodilation, health status, and rescue medication use. A total of 467 patients completed the lead-in study and 291 patients consented to participate in the extension. At study end, the percentages of patients who reported a treatment-emergent adverse event (TEAE) were similar for both treatments (200 μg, 77.4{\%}; 400 μg, 73.7{\%}). Incidence of anticholinergic TEAEs was low and similar for both treatments, with dry mouth reported in only 1 patient (400 μg). Cardiac TEAEs were reported by a similarly low percentage of patients (<5{\%} for any event in any group) with no apparent dose dependence. Improvements from baseline in lung function were greatest for patients who received continuous aclidinium treatment and those who were rerandomized from placebo to aclidinium 400 μg; these improvements were generally sustained throughout the study. Health status and overall rescue medication use was improved from baseline for both treatments. The safety profile of twice-daily aclidinium and sustained improvements in lung function and health status throughout the 52-week extension study support its use as a long-term maintenance treatment for patients with COPD. (Clinical trial registration number NCT00970268).",
keywords = "Bronchodilation, Health status, Symptoms, Tolerability",
author = "Anthony D'Urzo and Edward Kerwin and Stephen Rennard and Thomas He and Gil, {Esther Garcia} and Cynthia Caracta",
year = "2013",
month = "8",
day = "1",
doi = "10.3109/15412555.2013.791809",
language = "English (US)",
volume = "10",
pages = "500--510",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - One-year extension study of ACCORD COPD I

T2 - Safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD

AU - D'Urzo, Anthony

AU - Kerwin, Edward

AU - Rennard, Stephen

AU - He, Thomas

AU - Gil, Esther Garcia

AU - Caracta, Cynthia

PY - 2013/8/1

Y1 - 2013/8/1

N2 - This was a 52-week, double-blind, extension study in which COPD patients previously treated with twice-daily (BID) aclidinium bromide 200 μg or 400 μg during a 12-week lead-in study (ACCORD COPD I) continued the same treatment, while patients previously receiving placebo were rerandomized (1:1) to aclidinium 200 μg or 400 μg BID. The primary objective of this study was to evaluate the long-term safety and tolerability of aclidinium treatment. Efficacy outcomes included bronchodilation, health status, and rescue medication use. A total of 467 patients completed the lead-in study and 291 patients consented to participate in the extension. At study end, the percentages of patients who reported a treatment-emergent adverse event (TEAE) were similar for both treatments (200 μg, 77.4%; 400 μg, 73.7%). Incidence of anticholinergic TEAEs was low and similar for both treatments, with dry mouth reported in only 1 patient (400 μg). Cardiac TEAEs were reported by a similarly low percentage of patients (<5% for any event in any group) with no apparent dose dependence. Improvements from baseline in lung function were greatest for patients who received continuous aclidinium treatment and those who were rerandomized from placebo to aclidinium 400 μg; these improvements were generally sustained throughout the study. Health status and overall rescue medication use was improved from baseline for both treatments. The safety profile of twice-daily aclidinium and sustained improvements in lung function and health status throughout the 52-week extension study support its use as a long-term maintenance treatment for patients with COPD. (Clinical trial registration number NCT00970268).

AB - This was a 52-week, double-blind, extension study in which COPD patients previously treated with twice-daily (BID) aclidinium bromide 200 μg or 400 μg during a 12-week lead-in study (ACCORD COPD I) continued the same treatment, while patients previously receiving placebo were rerandomized (1:1) to aclidinium 200 μg or 400 μg BID. The primary objective of this study was to evaluate the long-term safety and tolerability of aclidinium treatment. Efficacy outcomes included bronchodilation, health status, and rescue medication use. A total of 467 patients completed the lead-in study and 291 patients consented to participate in the extension. At study end, the percentages of patients who reported a treatment-emergent adverse event (TEAE) were similar for both treatments (200 μg, 77.4%; 400 μg, 73.7%). Incidence of anticholinergic TEAEs was low and similar for both treatments, with dry mouth reported in only 1 patient (400 μg). Cardiac TEAEs were reported by a similarly low percentage of patients (<5% for any event in any group) with no apparent dose dependence. Improvements from baseline in lung function were greatest for patients who received continuous aclidinium treatment and those who were rerandomized from placebo to aclidinium 400 μg; these improvements were generally sustained throughout the study. Health status and overall rescue medication use was improved from baseline for both treatments. The safety profile of twice-daily aclidinium and sustained improvements in lung function and health status throughout the 52-week extension study support its use as a long-term maintenance treatment for patients with COPD. (Clinical trial registration number NCT00970268).

KW - Bronchodilation

KW - Health status

KW - Symptoms

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84880749808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880749808&partnerID=8YFLogxK

U2 - 10.3109/15412555.2013.791809

DO - 10.3109/15412555.2013.791809

M3 - Article

C2 - 23679347

AN - SCOPUS:84880749808

VL - 10

SP - 500

EP - 510

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 4

ER -